Corporate News – Cellebrite DI Ltd.
Cellebrite DI Ltd. (ticker: CLBT) closed the trading session of Tuesday, 20 October 2026, at a price of USD 11.37, reflecting a 1.04 % increase from the previous close. The 24‑hour volume for the stock was approximately USD 11.6 million, based on a total of 251.1 million shares outstanding. The company’s market capitalisation stands at USD 2.8 billion. Over the last month, the share price has fallen by 3.59 %.
The 200‑day simple moving average is USD 13.68. The highest price reached in the past 52 weeks was USD 19.98 on 13 November 2025, while the lowest price in the same period was USD 9.58 on 13 August 2026.
Recent Filing
On 19 October 2026, Cellebrite DI Ltd. filed a Form 4 with the U.S. Securities and Exchange Commission reporting a sale of ordinary shares by its Chief Financial Officer, David Barter. The transaction involved more than twelve thousand shares, executed at a weighted‑average price within a narrow range. Shares were transferred in several smaller trades and had been granted as restricted‑stock units in 2025, vesting in 2026. After the sale, Mr. Barter retained approximately three hundred thousand shares.
The filing also disclosed a Limited Power of Attorney signed by Mr. Barter on 15 September 2026. The power of attorney authorises a named group of attorneys to prepare and submit required Form 3, 4, and 5 filings on his behalf, obtain related information, and perform other acts under Section 16 of the U.S. Securities Exchange Act. The document confirms Mr. Barter’s continued compliance with regulatory reporting obligations.
Performance of Related Stocks (Last 24 Hours)
| Ticker | % Change | Current Price (USD) | Market Cap (USD mn) | P/E Ratio |
|---|---|---|---|---|
| ITRN | +1.11 % | 50.94 | 996.2 | 15.36 |
| NYAX | +0.96 % | 48.59 | 1,700 | 218.98 |
| RDWR | +5.12 % | 29.32 | 1,100 | 68.55 |
| DRTS | +2.69 % | 13.09 | 1,100 | – |
| ODD | +2.67 % | 23.53 | 1,000 | 67.91 |
Ituran Location And Control (ITRN) – The company announced that its third‑quarter 2026 financial results will be released on 24 November 2026. A video conference call for investors will be held at 9 a.m. Eastern Time, with additional slots for Pacific and Israel audiences. The call will be available via Zoom, and a recording will be posted afterward. Ituran’s headquarters are in Azour, Israel, and it operates globally with offices in the United States, Canada, Latin America, and India.
Nayax (NYAX) – Nayax filed a Form S‑8 on 20 October 2026 to register additional shares for issuance under its Global Equity Incentive Plan. The filing confirms that the company has authorised and reserved shares for options, restricted‑stock units, and other equity‑based awards. The registration statement includes prior disclosures, such as the company’s annual report and financial statements, and is supported by legal and accounting opinions.
Radware (RDWR) – The share price rose approximately five percent following the release of its latest financial snapshot. Analysts highlighted Radware’s GF score of 76, which is generally viewed as a positive signal for investors. No additional earnings or guidance details were provided in the brief report.
Alpha Tau Medical (DRTS) – The U.S. Food and Drug Administration approved an Investigational Device Exemption supplement extending Alpha Tau Medical’s REGAIN clinical trial for recurrent glioblastoma. The amendment increases the permitted enrolment from ten to twenty patients, adds new study endpoints—including progression‑free survival—and introduces a scheduled interim analysis. An abstract from the expanded trial, authored by Dr. Joshua Palmer of The Ohio State University, will be presented at the Society for Neuro‑Oncology’s 31st Annual Meeting in November.
Oddity Tech (ODD) – No additional corporate actions were reported beyond the 24‑hour price increase.
Company Overview
Cellebrite DI Ltd. is a software solution provider operating in the information technology sector. The company offers a digital intelligence platform for legally sanctioned investigations, enabling users to collect, review, analyze, and manage digital data throughout the investigative process. Cellebrite DI serves customers globally.
